Recombinant Human Tissue Factor (full length)

Recombinant Human Tissue Factor (full length)_x000D_ Catalog number: B2016596_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg _x000D_ Molecular Weight or Concentration: N/A_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: −80°C_x000D_ Keywords: Recombinant Tissue Factor (human, full length)_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References: _x000D_ 1: Rashid MH. Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation MAbs. 2022 Jan-Dec;14(1):2111748. _x000D_ 2: Jalili-Nik M, Soukhtanloo M, Mojarrad M, Sadeghian MH, Mashkani B. Challenges of expressing recombinant human tissue factor as a secreted protein in Pichia pastoris Prep Biochem Biotechnol. 2022;52(9):1001-1007. _x000D_ 3: Ho G, Narita M, Broze GJ Jr, Schwartz AL. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: implications for catabolism in vitro and in vivo Blood. 2000 Mar 15;95(6):1973-8._x000D_ 4: Butenas S. Comparison of natural and recombinant tissue factor proteins: new insights Biol Chem. 2013 Jul;394(7):819-29. _x000D_ 5: Bromage DI, Taferner S, Pillai M, Yellon DM, Davidson SM. A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies PLoS One. 2017 Apr 5;12(4):e0174447. _x000D_ 6: Gustafson ME, Junger KD, Wun TC, Foy BA, Diaz-Collier JA, Welsch DJ, Obukowicz MG, Bishop BF, Bild GS, Leimgruber RM, et al. Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli Protein Expr Purif. 1994 Jun;5(3):233-41. _x000D_ 7: Grandoni J, Perret G, Forier C. Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia Haemophilia. 2017 Mar;23(2):300-308. _x000D_ 8: Stidl R, Fuchs S, Bossard M, Siekmann J, Turecek PL, Putz M. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates Haemophilia. 2016 Jan;22(1):54-64. _x000D_ 9: Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces J Biol Chem. 1993 Apr 25;268(12):8704-10._x000D_ 10: Lindhout T, Willems G, Blezer R, Hemker HC. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor Biochem J. 1994 Jan 1;297 ( Pt 1)(Pt 1):131-6. _x000D_
Products Related to Recombinant Human Tissue Factor (full length) can be found at Enzymes

9000-83-3

Catalog Number: B2016596 (50 µg)

0.15

2

0.5